institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

CureVac Publishes Financial Results for the First Quarter of 2025 and Informs About Its Business Development

Summary by CureVac
FDA release for IND application for CVHNLC, the company's own off-the-shelf candidate for the treatment of squamous cell carcinomas of non-small cell lung cancer (sqNCLC); start of clinical trial expected for the second half of 2025; filed in Europe Clinical Trial Application; decision in the second quarter of 2025 expects glioblastoma study to be fully recruited with Part B of the Phase 1 study with CVGBM in the first quarter of 2025; Go/No-Go …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

CureVac broke the news in on Tuesday, May 20, 2025.
Sources are mostly out of (0)